Floatz logo

DALPICICLIB ISETIONATE

ER-positive Breast Cancer

Ruijin HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the ER-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
Ribociclib
National Cancer Institute (NCI)
Phase 3BB
Elacestrant
Kristina A. Fanucci
Phase 3BB
Trastuzumab Deruxtecan
Danish Breast Cancer Cooperative Group
Phase 3BB
Alpelisib
University of Miami
Phase 2B

View all 10 →

Same molecule, other indications

DALPICICLIB ISETIONATE is also rated in:

Breast CancerDormant
BB
Indicative ·
66 / 100
View asset →
Triple Negative Breast Cancer (TNBC)Dormant
B
Indicative ·
63 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →